NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has received $278,978 from the sale of its Fiscal Year 2008 net operating tax losses (NOL) and research tax credits through the NJ Economic Development Authority (NJEDA) pursuant to the rules, regulations and stipulations set forth by the NJ program.
